Seroatlas · Human Serome Atlas

CDR2

Cerebellar degeneration-related protein 2

Also known as: CDR2_HUMAN, CDR62, Yo

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q01850
Gene
CDR2
Ensembl
ENSG00000140743
Chromosome
16
Canonical length
454 aa
Protein class
Predicted intracellular proteins
Subcellular location
Nucleoplasm

OverviewNCBI Gene

Predicted to be located in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

454 residues, UniProt reviewed canonical sequence.

>Q01850|CDR2
     1  MLAENLVEEF EMKEDEPWYD HQDLQQDLQL AAELGKTLLD RNTELEDSVQ QMYTTNQEQL
    61  QEIEYLTKQV ELLRQMNEQH AKVYEQLDVT ARELEETNQK LVADSKASQQ KILSLTETIE
   121  CLQTNIDHLQ SQVEELKSSG QGRRSPGKCD QEKPAPSFAC LKELYDLRQH FVYDHVFAEK
   181  ITSLQGQPSP DEEENEHLKK TVTMLQAQLS LERQKRVTME EEYGLVLKEN SELEQQLGAT
   241  GAYRARALEL EAEVAEMRQM LQSEHPFVNG VEKLVPDSLY VPFKEPSQSL LEEMFLTVPE
   301  SHRKPLKRSS SETILSSLAG SDIVKGHEET CIRRAKAVKQ RGISLLHEVD TQYSALKVKY
   361  EELLKKCQEE QDSLSHKAVQ TSRAAAKDLT GVNAQSEPVA SGWELASVNP EPVSSPTTPP
   421  EYKALFKEIF SCIKKTKQEI DEQRTKYRSL SSHS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CDR2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.55
Highest tissue expression
70 nTPM

Expression across tissuesHPA

Tissue

  • retina: 70 nTPM
  • testis: 59 nTPM
  • thyroid gland: 48 nTPM
  • choroid plexus: 35 nTPM
  • thymus: 29 nTPM
  • blood vessel: 28 nTPM

Single-cell type

  • loop of henle epithelial cells: 296 nCPM
  • choroid plexus epithelial cells: 281 nCPM
  • proximal tubule cells: 280 nCPM
  • renal collecting duct principal cells: 217 nCPM
  • papillary tip epithelial cells: 190 nCPM
  • renal connecting tubule cells: 178 nCPM

Immune cell

  • basophil: 9.4 nTPM
  • T-reg: 6.7 nTPM
  • memory CD4 T-cell: 5.5 nTPM
  • naive CD4 T-cell: 4.4 nTPM
  • NK-cell: 4.3 nTPM
  • MAIT T-cell: 3.8 nTPM

Brain region

  • choroid plexus: 72 nTPM
  • basal ganglia: 42 nTPM
  • cerebellum: 32 nTPM
  • cerebral cortex: 25 nTPM
  • hypothalamus: 25 nTPM
  • hippocampal formation: 24 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about CDR2.

Disease | AutoantibodyPubMed

Conditions in which antibodies against CDR2 are reported. Each links to that disease's full target list.

Showing 9 of 18 — disease pages carrying at least 10 antigens.

ReferencesPubMed · IEDB

Publications for CDR2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

110 publications

Show 20 more of 110 total

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.03
gnomAD pLI
0
gnomAD missense Z
0.85
DepMap mean gene effect
-0.03
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of CDR2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CDR2 as an antibody target. Whether an autoantibody or antibody against CDR2 could matter depends on whether native CDR2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CDR2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label CDR2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/CDR2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...